Aug. 20 at 10:09 AM
$ALGS — the way I see it, cash from MASH supplements the real value here: CHB, the next 1L treatment. With non-voting shares approved in the latest vote, a
$500M range deal provides the pathway to CHB Phase 3. Once 2026–2027 data hits, this will be unstoppable.
